Cv-ca



CURRICULUM VITAECesar Alaniz, Pharm.D.715 Braeside PlaceAnn Arbor, MI 48103(734) 663-4871 (home)(734) 936-2244 (work)calaniz@umich.eduEDUCATION 1985-1986ASHP Accredited Residency in Clinical PharmacyVeterans Administration Medical CenterAnn Arbor, Michigan 1981-1985Doctor of PharmacyUniversity of CaliforniaSan Francisco, California 1978-1980Bachelor of Arts – PharmacologyUniversity of CaliforniaSanta Barbara, CaliforniaLICENSURE June, 1986MichiganPHARMACY PRACTICE EXPERIENCE 1995-PresentCLINICAL PHARMACIST ADULT MEDICINE INTENSIVE CARE UNITUniversity of Michigan Health SystemAnn Arbor, Michigan 1996-July, 1999CLINICAL PHARMACIST TEAM LEADERDepartment of Pharmacy ServicesUniversity of Michigan Health SystemAnn Arbor, Michigan 1986-1995CLINICAL PHARMACIST ADULT INTERNAL MEDICINEUniversity of Michigan Medical CenterAnn Arbor, MichiganACADEMIC APPOINTMENTS 2002-PresentCLINICAL ASSOCIATE PROFESSORCollege of PharmacyUniversity of Michigan, Ann Arbor 1989-PresentCLINICAL ASSISTANT PROFESSORCollege of PharmacyUniversity of Michigan, Ann Arbor 1985-1989CLINICAL INSTRUCTORCollege of PharmacyUniversity of Michigan, Ann ArborTEACHING EXPERIENCE: COURSES COORDINATED 2011-Direct Patient CareCollege of PharmacyUniversity of Michigan, Ann Arbor 2008-Introduction to Critical Care PharmacotherapyCollege of PharmacyUniversity of Michigan, Ann Arbor 1990-1999"Clinical Pharmacokinetics"College of PharmacyUniversity of Michigan, Ann Arbor 1987-91"Drug Therapy of Parasitic Diseases"College of PharmacyUniversity of Michigan, Ann ArborTEACHING EXPERIENCE: LECTURES GIVEN 2008-Introduction to Critical Care Pharmacotherapy – “Introduction, ARDS, Acute Liver Failure”College of PharmacyUniversity of Michigan, Ann Arbor 1993-2007"Clinical Therapeutics – Liver Disease"College of PharmacyUniversity of Michigan, Ann Arbor 2000-2004“Drug Use Evaluation”College of PharmacyUniversity of Michigan, Ann Arbor 1991-1998"Clinical Pharmacology and Therapeutics – Dosing Considerations in Disease States"School of MedicineUniversity of Michigan, Ann Arbor 1990-1999"Phenytoin and Cyclosporine Pharmacokinetics"College of PharmacyUniversity of Michigan, Ann Arbor 1991"Sexually Transmitted Diseases"School of NursingUniversity of Michigan, Ann Arbor 1987-91"Drug Therapy of Parasitic Diseases"College of PharmacyUniversity of Michigan, Ann Arbor 1987-90"Clinical Therapeutics - Management of Seizures"College of PharmacyUniversity of Michigan, Ann Arbor 1989, 1990"Oral Diagnosis - Drugs Used in Dentistry"School of MedicineUniversity of Michigan Medical Center 1986"Introduction to Patient Monitoring"College of PharmacyUniversity of Michigan, Ann ArborAWARDS 2008-09TEACHING EXCELLENCE AWARDGiven by 4-year pharmacy classCollege of PharmacyUniversity of Michigan, Ann Arbor 1998PRECEPTOR OF THE YEARCollege of Pharmacy University of Michigan, Ann ArborCOMMITTEES – HOSPITAL 2013-2016ALCOHOL WITHDRAWAL GUIDELINES COMMITTEEUniversity of Michigan Health System, Ann Arbor 2009-ANTICOAGULATION COMMITTEEUniversity of Michigan Health System, Ann Arbor 2010ANTICOAGULATION CLINICAL PHARMCIST SEACH COMMITTEEUniversity of Michigan Department of Pharmacy 1997-PresentPHARMACY AND THERAPEUTICS COMMITTEEUniversity of Michigan Health System, Ann Arbor 1996-PresentCRITICAL CARE STEERING COMMITTEEUniversity of Michigan Health System, Ann Arbor 1995-PresentMEDICAL ICU MULTIDISCIPLINARY COMMITTEEUniversity of Michigan Health System, Ann Arbor 2005-2006TIMED BLOOD DRAWS LEAN TEAMUniversity of Michigan Health System, Ann Arbor 2005-2006DVT RISK ASSESSMENT AND PROPHYLAXISUniversity of Michigan Health System, Ann Arbor 2005-2006HEPARIN ORDERS MANAGEMENT PROJECTUniversity of Michigan Health System, Ann Arbor 2005-2006SMOKING CESSATION POLICYUniversity of Michigan Health System, Ann Arbor 2004CHAIR, PHARMACY CARDIOLOGY SEARCH COMMITTEEUniversity of Michigan Health System, Ann Arbor. 1997-2001QUALITY IMPROVEMENT COMMITTEEDepartment of Pharmacy ServicesUniversity of Michigan Health System, Ann Arbor 1996-2001CHAIRPERSON, RESIDENCY ADVISORY COMMITTEEUniversity of Michigan Health System, Ann Arbor 1996-1997IV STANDARDIZATION COMMITTEEUniversity of Michigan Health System, Ann Arbor 1989-1996DRUG UTILIZATION EVALUATION COMMITTEEUniversity of Michigan Hospitals, Ann Arbor 1991-1995CLINICAL TOTAL QUALITY IMPROVEMENT TEAMAppropriate Therapeutic Drug MonitoringUniversity of Michigan Hospitals, Ann Arbor 1992-1994BLOOD DRAW QUALITY IMPROVEMENT TEAMAppropriate Utilization of Phlebotomy PersonnelUniversity of Michigan Hospitals, Ann ArborCOMMITTEES - COLLEGE OF PHARMACY 2013-PresentHONORS COUNCILUniversity of Michigan College of Pharmacy 2009-PresentADMISSIONS COMMITTEEUniversity of Michigan College of Pharmacy 2013CHAIR, GENERAL SURGERY/NUTRITION SUPPORTSEARCH COMMITTEEUniversity of Michigan College of Pharmacy 2004-2013PHARM D. INVESTIGATIONS COMMITTEEUniversity of Michigan College of Pharmacy 2012CHAIR, GENERAL SURGERY/NUTRITION SUPPORTSEARCH COMMITTEEUniversity of Michigan College of Pharmacy 2005-2006SURGICAL ICU SEARCH COMMITTEEUniversity of Michigan College of Pharmacy 2005-2006FACULTY EVALUATION AND DEVELOPMENT COMMITTEEUniversity of Michigan College of Pharmacy 2004AD-HOC PROMOTIONS COMMITTEEUniversity of Michigan College of Pharmacy 2003MEMBER, DEAN SEARCH ADVISORY COMMITTEE 2003MEMBER, DRUG INFORMATION SEARCH COMMITTEE 2000-PresentCLINICAL RESEARCH REVIEW COMMITTEE 2002CHAIR, PROMOTIONS AD-HOC COMMITTEE 1999-2000CHAIR, PHARMACY TRANSPLANT SURGERY SEARCH COMMITTEE 1999CHAIR, PHARMACY GENERAL SURGERY SEARCH COMMITTEE 1999DEPARTMENTAL CHAIR SEARCH COMMITTEECOMMITTEES – NATIONAL December 12-13, 2002MEMBER, ADVISORY COMMITTEE for EPCP, Emerging Pathogens Consult Program 2000-2003MEMBER, PROGRAM COMMITTEE of the Clinical Pharmacy/Pharmacology Section of Society of Critical Care November 10-11, 2000MEMBER, ADVISORY COMMITTEE for EPIC, Emerging Pathogens and Interventions for Clinicians, West Palm Beach, MITTEES – REGIONAL 2008-MEMBER, ADVISORY COMMITTEE for Keystone Surviving Sepsis CampaignMichigan Hospitals AssociationPROFESSIONAL ACTIVITIES January 2010, 2012, 2013, 2014MODERATOR, POSTER SESSIONSSociety of Critical Care Medicine Annual CongressMiami, FL 2008-PresentREVIEWER, ABSTRACTSSociety of Critical Care Medicine Annual Congress 2013-PresentREVIEWER, CLINICAL THERAPEUTICS 2013-PresentREVIEWER, JOURNAL OF PHARMACY PRACTICE 2011-PresentREVIEWER, BIOMEDICAL CENTRAL: GERIATRICS 2004- PresentREVIEWER, P & T 1994-PresentREVIEWER, THE ANNALS OF PHARMACOTHERAPY 1998-PresentREVIEWER, THE JOURNAL OF PHARMACY TECHNOLOGY 1999-PresentREVIEWER, THE JOURNAL OF MANAGED CARE 2005Chapters Reviewed: Drugs Affecting the Cardiovascular and Renal Systems in Drugs and the Nursing Process, Elsevier, 2005. 1993-1997REVIEWER, POSTER PRESENTATIONSThe American Society of Health-System PharmacyPRESENTATIONS AND LECTURES“Knowledge of appropriate acetaminophen use and potential toxicity: a survey of female college students.” Stumpf JL, Liao A, Nguyen S, Skyles A, Alaniz C. Poster presentation at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December, 2015.“Risk Factors for Piperacillin/tazobactam-Resistant Gram-Negative Pathogens in Critically Ill Patients with Healthcare Associated Pneumonia”. Patel TS, Alaniz C, Fan D, Nagel JL. .55th Interscience Conference on Antimicrobial Agents and Chemotherapy.? San Diego, CA. Sept 2015.“Risk Factor Evaluation For Piperacillin/tazobactam Resistance In Critically Ill Patients With Healthcare Associated Pneumonia”. Patel TS, Alaniz C, Fan D, Nagel JL. 18th Annual Making a Difference in Infectious Diseases Conference. Orlando, FL. May 2015. “Recurrent c. difficile infection in intensive care unit patients.” Jasiak N, Alaniz C. Rao K, Veltman K, Nagel JL. Poster Presentation at the International Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 2014..“Comparison of aPTT versus anti-IIa monitoring for argatroban” Vu N, Pogue K, Hannigan S, Dorsch M, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Congress, San Francisco, CA, January 2014.“Should the Rumack-Matthew nomogram be used in pediatric patients?” Chan C, Vu L, Tsu T, Stumpf JL, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Congress, San Francisco, CA, January 2014.“Management of Alcohol Withdrawal” Invited presentation at the Michigan Pharmacists Association, Novi, MI, November, 2013.“Association between liver disease and QT prolongation following anti-psychotic treatment in the ICU.” Williams B, Alaniz C. Poster Presentation at the American College of Clinical Pharmacy Annual Meeting, Pheonix, AZ October 2013.“Impact of body weight on albumin replacement in patients with spontaneous bacterial peritonitis.” Harrison M, Leung J, Shen K, Regal R, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Congress, San Juan, PR, January 2013.“Impact of body weight on potassium replacement in critically ill patients.” Koors M, Truong V, Pleva M, Dorsch M, Alaniz C, Hyzy RC.. Poster Presentation at the Society of Critical Care Medicine Congress, San Juan, PR, January 2013.“Comparison of clinical outcomes with azithromycin and fluoroquinolones in the treatment of legionella pneumonia.” Rarus R, Crowley A, Nagel J, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Congress, San Juan, PR, January 2013.“Evaluating the efficacy and complications of chemoprophylaxis for venous thromboembolism in otolaryngology”. Bahl V, Shuman AG, Hsou M, Jackson CR, Alaniz C, Chepeha DB, Bradford CR. Poster presentation at the International Conference on Head and Neck Cancer, Toronto, ON, Canada, July 2012.“Five year experience with hydrocortisone use for septic shock.” Edwin S, Nielsen J, Brach L, Strachan K, Alaniz C, Hyzy RC. Poster Presentation at the Society of Critical Care Medicine Congress, Houston, TX, January 2011.“Therapeutic anticoagulation with enoxaparin in obese patients” Edwin S, Nielsen J, Mehta V, Dorsch M, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Congress, San Diego, CA, January 2011.“Incidence of Hypoglycemia Associated with Less Intensive Insulin Therapy: Depends on the Definition of Hypoglycemia.” Pleva M, Widlicki M, Brach C, Strachan CL, Alaniz C, Hyzy RC, Poster Presentation at the Society of Critical Care Medicine Congress, Miami, FL, January 2010.“Vasopressor Selection and Maximum Infusion Rates in Septic Shock.” Pollard S, Pleva M, Hyzy RC, Alaniz C, Poster Presentation at the Society of Critical Care Medicine Congress, Miami, FL, January 2010.“Applicability of the Rumack-Matthew Nomogram to a Pediatric Population.” Toderico A, Ebaugh S, Stumpf JL, Alaniz C. Poster Presentation at the American Society of Health Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December, 2009.“Does body weight impact the efficacy of vasopressin the management of septic shock?” Miller JT, Alaniz C, Kraft MD, Welage LS. Poster Presentation at the Society of Critical Care Medicine Congress, Nashville, TN, February, 2009.“Comparison of IV metoprolol continuous infusion versus intermittent infusion in surgical intensive care unit patients.” Kraft MD, Alaniz C, Hayanga AJ, et. al. Poster Presentation at the American College of Clinical Pharmacy Meeting, Pheonix, AZ, April, 2008.“Acetaminophen induced liver failure: epidemiology, management and need for increased awareness.” Alaniz C, Erickson SR, Dietz H. Presentation, Michigan Pharmacist Association Annual Convention and Exposition, Dearborn, MI. February, 2008.“Evaluating accuracy of diagnosing heparin-induced thrombocytopenia in a University Hospital. Mohammad D, Lindquist K, Lewandowski A, Alaniz C, Stevenson J. Poster Presentation at the Society of Critical Care Medicine Meeting, Honolulu HI, February, 2008.“Octreotide versus octreotide and continuous infusion pantoprazole in the treatment of variceal hemorrhage.” Mohammad R, Smigel J, Tripp B, Welage L, Alaniz C. Poster Presentation at the American College of Clinical Pharmacy Meeting, Memphis TN, April, 2007.“Clostridium difficile associated disease.” Invited presentation, Michigan Pharmacist Association Annual Convention and Exposition, Dearborn, MI, March, 2007“Impact and compliance with a protocol for Factor VIIa use.” Mohammad D, Stevenson J, Butler S, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Annual Congress, Orlando, FL, February, 2007. “DVT Prevention – Can We Do Better? Implementing a Risk Assessment Tool to Improve Adherence to Guidelines for Medical Inpatients.” Bump G, Alaniz C. Poster Presentation at Society of Hospitalists Medicine Meeting, Washington D.C., May, 2006.“Increased length of stay in medical intensive care unit associated with vancomycin-resistant enterococci surveillance.” Alaniz C, Arndt J, Brach C, Adamczyk M., Hyzy R, McClish D, Hay J, Lenart P. Poster Presentation at the Society of Critical Care Medicine Meeting, San Francisco, CA, Jan 2006. “Outcome of an insulin infusion protocol on blood glucose control in patients undergoing cardiac surgery.” Khanderia, U. Iaderosa, R. Edillo, NP. Alaniz, C. Gianchandani, R. Poster presentation at the ASHP Midyear Clnical Meeting, Las Vegas, NV, Dec, 2005.“Judicious Use of Antibiotics in Hospital Acquired Pneumonia” St. Joseph’s Mercy Hospital, Ypsilanti, MI April 25, 2005. “The impact of educational interventions on the use of serum cyanide concentrations in patients receiving nitroprusside.” Alaniz C, Caruthers R, Butler SO. Poster Presentation at the Society of Critical Care Medicine Meeting, Phoenix, AZ, Jan 2005. “Use and satisfaction of daily goals for patients in a medical intensive care unit.” Adamczyk M., Hyzy R, Bria B, Campbell DA, Thompson M., Strachan C, Brach C, Keesler C, McClish D, Hay J, Lenart P, Alaniz C. Poster Presentation at the Society of Critical Care Medicine Meeting, Phoenix, AZ, Jan 2005. “Discordance of international classification of diseases, 9th edition (ICD-9) coding for severe sepsis at a university hospital.” Butler SO, Nielsen J, Alaniz C, Welage LS. Poster Presentation at the Society of Critical Care Medicine Meeting, Phoenix, AZ, Jan 2005. Impact of a continuous insulin infusion protocol on sternal wound infections in patients undergoing cardiac surgery. Khanderia U, Edillo PN, Iaderosa R, Alaniz C. Poster presentation at the ASHP Midyear Clinical Meeting Orlando, FL, Dec, 2004.“Steroids in Sepsis” Surviving Sepsis Campaign: Making it a Reality in Michigan, Brighton, MI. November 6, 2004.“Extended Spectrum Beta-Lactamases” St. Joseph’s Mercy Hospital, Ypsilanti, MI September 16, 2004. “Pseudomonas aeruginosa and acinetobacter baumanii” Select Specialty, Mt. Clemens, MI. April 24, 2004.. “Vancomycin Resistant Enterococcus”, Detroit Receiving Hospital, Detroit, MI. December 18, 2003.“Knowledge of acetaminophen doses and potential toxicities in an adult clinic population.” Skyles AG, Stumpf JL, Alaniz C, Erickson S. Poster presentation at the ASHP Midyear Clnical Meeting, New Orleans, LA, Dec 2003..Fedewa K, Collins CD, Alaniz C. Compliance with institutional guidelines on the use of vancomycin in a medical intensive care unit. Poster presentation at the ASHP Midyear Clinical Meeting. New Orleans, LA, Dec,2003.Janusz, JL. Alaniz, C. Etiologies and outcomes of patients admitted to a university hospital with presumed acetaminophen toxicity. Poster presentation at the ASHP Midyear Clinical Meeting. New Orleans, LA, Dec, 2003“Pseudomonas aeruginosa and acinetobacter baumanii” St. Joseph’s Mercy Hospital, Ypsilanti, MI. November 7, 2003. “Antibiotic selection in the management of nosocomial pneumonia” CCMU Nursing Education, UMHS. October 22, 2003."Multi-drug resistance" Oakwood Hospital, Dearborn, MI. September 18, 2003.“Review of fungal isolates over a 7-year period in medical, surgical and trauma-burn units in a university hospital.” Alaniz C, Depestel D, Pierson C. Poster presentation at the Society of Critical Care Medicine Educational and Scientific Symposium. San Antonio, TX January 28, 2003.“Management of Febrile Neutropenia” Grand Rounds presented at Bronson Medical Center, Kalamazoo, MI, February 5, 2003.“Update on Esophageal Varices” Platform presentation at the ASHP Midyear Clinical Meeting, December 10, 2002.“Toxicology” CE Presentation to MICU nurses, University of Michigan Health System, Ann Arbor, October 7 and 11, 2002.“C. Difficile Associated Disease” CE Presentation, Emerging Pathogens and Interventions for Clinicians Symposium. Lake Geneva, WI, July 19, 2002“Resistance in the ICU”, Lecture presented to Clinical staff, Oakwood Hospital, Southfield, MI, August 28, 2001.“Pseudomonas resistance”, Presented to clinical staff, Chelsea Hospital, Chelsea, MI, October 24, 2001.“Vancomycin Resistant Enterococcus”, Emerging Pathogens and Interventions for Clinicians Symposium. Novi, MI, November 17, 2001.“Susceptibility of Pseudomonas aeruginosa Isolates to Fluoroquinolones in a Medical IntensiveCare Unit: The Need for Unit-Specific Data.” Alaniz C, Depestel D, Pierson C. Poster presentation at the Society of Critical Care Medicine Educational and Scientific Symposium. San Diego, CA January 28, 2002.“Continuous Beta-lactam Infusions”, Presented to clinical staff, Ivyonix Corporation. Livonia, MI, August 21, 2001."Choice of Sedative and a Continous Infusion Sedation Protocol: Impact on Outcomes and Healthcare Costs in a Medical Intensive Care Unit. Kuru T, Alaniz C, Kewman S, Diccion S, Toews G, Watts C. Poster Presentation at the Society of Critical Care Medicine Educational and Scientific Symposium. San Francisco, CA, February 13, 2001.“Issues in Antibiotic Therapy”, Presentation at the Medical-Surgical Nursing Conference, Ann Arbor, MI, April 28, 2000."Choice of Sedative Agent in Patients with ARDS Undergoing Low Tidal Volume Mechanical Ventilation,” Kuru T, Alaniz C, Kewman S, Strachan C, Diccion S, Toews G, Watts C. Poster presentation at the SCCM Educational and Scientific Symposium. Orlando, FL, February 15, 2000."Piperacillin-Tazobactam: Review and Outlook” Presentation to Infectious Disease Service, Henry Ford Hospital, Detroit, MI, October 22, 1999.“Antibiotics in the ICU”, One-hour CE program presented to Critical Care Medicine Unit, University of Michigan Health System, Ann Arbor, MI, October 11, 1999."Use of Broad-Spectrum Antibiotics in the ICU” Presentation at HomeMed, Ann Arbor, MI, May 6, 1999.“Implementation of Single Daily Dose Aminoglycosides to Reduce the Incidence of Nephrotoxicity in Critically Ill Patients,” Odeh R, Alaniz C, Hayes S. Poster presentation at the ACCP International Meeting, Orlando, FL, April 14, 1999."Management of Hypertensive Emergencies in a University Hospital,” Klepack E, Alaniz C, Stumpf JL. Poster presentation at the ASHP Midyear Clinical Meeting, Las Vegas NV, December 9, 1998."Single Daily Dose Aminoglycosides and the Incidence of Nephrotoxicity in Critically Ill Patients,” Odeh R, Alaniz C, Hayes S. Poster presentation at the ASHP Midyear Clinical Meeting, Las Vegas, NV, December 6, 1998."Antibiotic Selection and Emergence of VRE.” Presented to General Surgery Residents, University of Michigan Health System, Ann Arbor, MI, August 8, 1998."Update on Antimicrobial Therapy.” Alaniz C. Presentation at Ivonyx-Complete Infusion Co., Livonia MI, May 12, 1998."Once Daily Aminoglycoside Administration in Intensive Care Units,” Odeh R, Alaniz C, Hayes S. Platform presentation at the Institute for Healthcare Improvement Annual Meeting, Atlanta, GA, November 13, 1998."Vancomycin Resistant Enterococcus,” CME presentation at the Community Health Center of Branch County, Coldwater, MI, March 18, 1998."Antibiotic Selection in the ICU.” Alaniz C. Presentation to the Pulmonary Critical Care Associates of Ann Arbor, Ypsilanti, MI January 16, 1998."Sedation in the ICU” Alaniz C. Presentation to Oakwood Hospital Pharmacists, Dearborn, MI, December 5, 1997."Antibiotic Algorithms in the Medical ICU.” Alaniz C. presentation to Mercy Hospital Pharmacists, St. Clair, MI, September 10, 1997."Pharmacoeconomics in the Intensive Care Unit,” Alaniz C. CE presentation at the American Association of Critical Care Nurses Meeting, Novi, MI, May 8, 1997."Determination and Evaluation of the Therapeutic Range of Serum Phenytoin Concentrations at a University Hospital. Alaniz C, Sony A. Poster presentation at the ASHP Midyear Clinical Meeting, New Orleans, LA, December 10, 1996."Cost-effective Use of Neuromuscular Blocking Agents and Sedative Hypnotic Drugs in the ICU,” Watts C, Strachan C, Guglielmo D, Chaffee B, Alaniz C, Diccion S, Kewman S. Poster presentation at the Institute for Healthcare Improvement Annual Meeting, Boston, MA, December 12, 1996."What is the Association Between Corticosteroid Use and Peptic Ulcer Disease?" Alaniz C. CE presentation at the Michigan Pharmacist Association Interim Meeting, Dearborn, MI, February 21, 1993."Evaluation of Intravenous Phosphorous Replacement in a University Hospital," Alaniz C, Rice TL. Poster presentation at the ASHP Midyear Clinical Meeting, Orlando, FL, December 8, 1992."Overview of Basic Pharmacokinetics," Alaniz C. Presentation at the American Association for Clinical Chemistry Meeting, Dearborn, MI, November 19, 1992."Treatment of Acute Severe Hypophosphatemia,” Alaniz C. CE presentation at the Michigan Pharmacist Association Interim Meeting, Dearborn, MI, February 23, 1992."Computer-Assisted Monitoring and Pharmacist-Initiated Modification of Excessive Imipenem-Cilastatin Dosing," Townsend KA, Alaniz C, Ryan ML, et al. Platform presentation at the ASHP Annual Meeting, San Diego, CA, June 4, 1991."Imipenem-Cilastatin Use in University Hospital: Evaluation of Dosing and Survey of Adverse Effects," Townsend KA, Alaniz C, Stumpf JL. Poster presentation at the ASHP Midyear Clinical Meeting, Las Vegas, NV, December 6, 1990."The Use of Norfloxacin in a University Hospital," Alaniz C, Stumpf JL, Townsend KA. Poster presentation at the ASHP Midyear Clinical Meeting, Atlanta, GA, December 5, 1989. RESEARCHAlaniz C, Edwin S, Nielsen J, Mehta V, Dorsch M. Dosing of enoxaparin in obese patients: a population pharmacokinetic analysis. Alaniz C, Larkin A, Dorsch M, Pleva M, Btaiche I. Impact of body weight on potassium replacement in critically ill patients. Alaniz C, Regal RR. Evaluation of albumin infusions in patients with spontaneous bacterial peritonitis.Nagel J, Alaniz C. Retrospective evaluation of azithromycin versus levofloxacin in the management of legionella pneumonia.GRANTSAlaniz, C. 2005, Grant, Amgen Inc. ASSESS Study: $28,156.25Alaniz, C. 2004, Unrestricted grant, Wyeth Pharmaceuticals: $2,000.Lynda Welage, Cesar Alaniz, Jessica Ellis, Robert Hyzy, Andrea Mitchell, Carol Kauffman. 2003, Grant, Pharmacia Corporation: $57,702.Alaniz, C. 2003, Unrestricted grant, Lilly Corporation: $500.Alaniz, C. 2003, Unrestricted grant, Wyeth Pharmaceuticals: $1,000.Depestel D, Alaniz C. 2001, Unrestricted grant, Otho-McNeil Corporation: $4,000Alaniz C, Depestel D. 2001, Unrestricted grant, Wyeth Pharmaceuticals: $5,000PUBLICATIONSVu N, Jaynes E, Chan C, Dorsch M, Pipe S, Alaniz C. Argatroban monitoring: aptt versus chromogenic assay. Am J Hematol. 2016;91:e303-4.Jasiak NM, Alaniz C, Rao K, Veltman K, Nagel JL. Recurrent clostridium difficile infection in intensive care unit patients. Am J Infect Contol. 2016;44:36-40.Pollard S, Edwin SB, Alaniz C. Vasopressor and inotropic management in patients with septic shock. PT. 2015;40:438-50.Alaniz C, Hyzy RC. Time to declare a moratorium on stress ulcer prophylaxis in the critically ill. Crit Care Med. 2014;42:e36-37.Nagel JL, Rarus RE, Crowley AW, Alaniz C, Pogue JM. Retrospective analysis of azithromycin versus fluoroquinolones for the treatment of legionella pneumonia. PT. 2014;39:204-205.Alaniz C, Pollard S. Vasopressor dosing in septic shock. Crit Care Med. 2013 Dec;41(12):e483-4. Kennedy DM, Alaniz C. Apparent argatroban resistance in a patient with elevated factor VIII levels. Ann Pharmacother. 2013 Jul-Aug;47(7-8):e29.Mohammad RA,Regal R, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother 2012; 46:1559-63.Alaniz C, Pogue JM. Vancomycin versus linezolid in the treatment of methicillin-resistant staphylococcus aureus pneumonia: implications of the zephyr trial. Ann Pharmacother 2012;46:1432-5.Miller JT, Welage LS, Kraft MD, Alaniz C. Does body weight impact the efficacy of vasopressin in the management of septic shock? J Crit Care. 2012;27:289-93.Pettit RS, Zimmerman CR, Alaniz C, Dorsch MP. Cost analysis before and after implementation of a computerized physician order entry form for enoxaparin. P T. 2012;37:107-11.Alaniz C, Hyzy RC. Albumin meta-analysis and epochs of care. Crit Care Med. 2011;39:1852.Alaniz C. Management of bleeding esophageal varices, in Pharmacotherapy Casebook: A Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, July 2011.Pogue JM, Alaniz C, Carver PL, Pleva M, Newton D, DePestel DD. Role of unit-specific antibiograms for improving the selection of appropriate empiric therapy for gram-negative pneumonia. Infect Control Hosp Epidemiol. 2011;32:289-92.Alaniz C, Mohammed RA, Welage LC. High dose PPIs in patients with variceal hemorrhage. Arch Intern Med. 2010;170:1698.Alaniz C. An update on activated protein c (Xigris) in the management of sepsis. PT. 2010;35:504-29.Alaniz C, Hyzy RC. Glycemic control in the intensive care unit. Ann Intern Med. 2010;5:65-6.Alaniz C, Regal R. Spontaneous Bacterial Peritonitis. P and T. 2009;34:204-10.Alaniz, C., Mohammad, R. A., & Welage, L. S. (2009). Continuous infusion of pantoprazole with octreotide does not improve management of variceal hemorrhage. Pharmacotherapy, 29(3), 248-254.Alaniz C, Hyzy R. Diagnosing Adrenal Insufficiency. Crit Care Med. 2008;36:3281-2.Alaniz C. Management of bleeding esophageal varices, in Pharmacotherapy Casebook: A Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, August 2008.Btaiche IF, Mohammad RA, Alaniz C, Mueller BA. Amino acid requirements in critically ill patients with acute kidney injury treated with renal replacement therapy. Pharmacotherapy. 2008;28:600-13.Stumpf JL, Skyles AJ, Alaniz C, Erickson SR. Knowledge of appropriate acetaminophen doses and potential toxicities in an adult clinic population. J Am Pharm Assoc. 2007;47:35-41.Alaniz C, Janusz J. A retrospective study of the etiologies and outcomes of patients admitted to a university hospital with presumed acetaminophen toxicity. Hosp Pharm. 2007;42:126-132.Alaniz C. Selection of sedative for mechanically ventilated patients. Crit Care Med. 2007;25:327.Eschenauer GA, Fedewa K, Collins CD, Alaniz C. Compliance with an institutional guidelines on the use of vancomycin in a medical intensive care unit. Hosp Pharm. 2006;41:749-53.Butler, SO. Btaiche, IF. Alaniz, C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy. 25(7): p 963-976. 2005.Alaniz C. Management of bleeding esophageal varices, in Pharmacotherapy Casebook: A Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, March 2005.Alaniz C, Lam N. Hepatitis C, in Pharmacotherapy Casebook: a Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, March 2005.Alaniz C, Watts B. Monitoring cyanide toxicity in patients receiving nitroprusside therapy. Ann Pharm Ther, 2005;39:388-9.Ilag LL, Kronick S, Ernst RD, Grondin L,Alaniz C, Liu L, Herman WH. Impact of a critical pathway on inpatient management of diabetic ketoacidosis. Diabetes Res Clin Prac. 2003;62:23-32.Welage LS, Ellis J, Alaniz C. Gastrointestinal alterations in the critically ill. Pharmacy Practice News. July 2003:46-51.Leady M, Kraft M, Alaniz C. Recombinant human activated protein C or drotrecogin alpha. P & T. 2002;141:190-4.Alaniz C. Management of bleeding esophageal varices, in Pharmacotherapy Casebook: A Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, March 2002:123-4.Quigley C, Alaniz C. Hepatic encephalopathy, in Pharmacotherapy Casebook: A Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, March 2002:125-6.Alaniz C, Lam N. Hepatitis C, in Pharmacotherapy Casebook: a Patient-Focused Approach. Schwinghammer T, ed. McGraw-Hill, March 2002:136-8.Good K, Alaniz C. Does once daily dosing of aminoglycosides obviate the need for pharmacy based pharmacokinetic monitoring of aminoglycosides? ASHP Midyear Clinical Meeting. 35(Dec): P-182R. 2000. Abstract.Alaniz, C. Fisher, J. Chaffee, BW. Comparison of two dosing regimens of piperacillin/tazobactam in the treatment of nosocomial pneumonia. ASHP Midyear Clinical Meeting. 34(Dec): p P-245R. 1999. Abstract.Rorstad, A. Alaniz, C. Montgomery, P. Analysis of low-molecular-weight heparin use at a university hospital. ASHP Midyear Clinical Meeting. 34(Dec): p P-97R. 1999. Abstract.Alaniz C. Complications of cirrhosis, In: Carter BL, ed. Pharmacotherapy Self Assessment Program, 3rd ed. Kansas City: American College of Clinical Pharmacy. October, 1999.Alaniz C. Mangement of bleeding esophageal varices, In: Schwinghammer T, ed. Pharmacotherapy a Patient-Focused Approach, 2nd ed. Stamford, CT: Appleton & Lange, August 1999.UMHS Antibiotic Subcommittee. The university of michigan hospitals and health centers guidelines for antimicrobial use, 1999-2000. Contributor.Alaniz C. Cirrhotic ascites, In: Schwinghammer T, ed. Pharmacotherapy a Patient-Focused Approach, 1st ed. Stamford, CT: Appleton & Lange, 1996.Gottschling LL, Alaniz C. Thrombosis resulting from heparin therapy. Pharmacotherapy. 1996;16:469-72.Stumpf, JL. Alaniz, C. Btaiche, I. Albumin use following large volume paracentesis of cirrhotic ascites: benefit of an ongoing pharmacy intervention. ASHP Midyear Clinical Meeting. 30(Dec): p P-80(E). 1995. Abstract.Alaniz, C. Ryan, ML. Rice, TL. Welage, L. Improving therapeutic drug monitoring through a total quality management approach. ASHP Midyear Clinical Meeting. 30(Dec): p MCS-9. 1995. Abstract.Alaniz C. Corticosteroid-induced peptic ulcer disease: Distinguishing myth from reality. Michigan Drug Letter, University of Michigan Medical Center. 1995;14:(issue 8).Patel, BH. Alaniz, C. Stumpf, JL. Montgomery, PA. Rice, TL. Townsend, KA. Comparison of clinical outcomes following two methods of vancomycin therapy monitoring. ASHP Annual Meeting. 51(Jun): p P-44(R). 1994. Abstract.Alaniz, C. Rice, TL. Improving theophylline therapeutic monitoring: total quality approach. ASHP Midyear Clinical Meeting. 28(Dec): p P-360(R). 1993. Abstract.Alaniz C, Brosius FC, Palmieri J. Pharmacologic management of adult idiopathic nephrotic syndrome. Clin Pharm. 1993;12:429-39.Alaniz C, Rice T. Evaluation of intravenous phosphate replacement in a University Hospital. Hosp Pharm. 1993;28:385,388,391-2.Stumpf, JL. Alaniz, C. Rice, TL. Evaluation of the monitoring of vancomycin therapy: appropriateness of serum vancomycin levels in a university hospital. ASHP Midyear Clinical Meeting. 27(Dec): p P-658R. 1992. Abstract.Shaheen B, Alaniz C. Calcium-channel blockers used in combination. Ann Pharmacother.1992;26:1387-8.Townsend KA, Alaniz C, Stumpf JL, Fekety FR. Imipenem-cilastatin use: Evaluation of dosing and survey of adverse effects. Hosp Pharm. 1992;27:298,303-5,308-10.Rice, TL. Alaniz, C. Rapid intravenous phosphorus administration in the treatment of severe hypophosphatemia. ASHP Midyear Clinical Meeting. 26(Dec): p CR-13. 1991. Abstract.Alaniz C, Stumpf JL, Townsend KA. The use of norfloxacin in a University Hospital. Hosp Pharm. 1991;26:707-10,19.Alaniz C. The use of octreotide in the management of diabetes mellitus. Michigan Drug Letter, University of Michigan Medical Center. 1990;9(issue 3).Alaniz C. The management of cirrhotic ascites. Clin Pharm. 1989;8:645-54.Colburn PA, Carver PA, Montgomery PA, Alaniz C, Chaffee B, Amesbury B. Appropriate but not cost-effective ceftazidime use in a University Hospital. Hosp Pharm. 1989;911-14,916,928. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download